Altimmune Inc.

ALT | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.27

+$0.02 (+0.62%)

At close: Sep 21, 2026, 4:00 PM ET

$3.30

+$0.03 (+0.92%)

Pre-market: Sep 22, 2026, 6:06 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.62%

(1D)

Rating

Updated: Aug 25, 2026

31.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $635.93M

1D Range

3.25 3.32

52W Range

2.56 6.44

Valuation (TTM)

PE -4.19

PB 1.34

EV/EBITDA -3.92

Valuation (NTM)

Forward PE N/A

Forward PEG -0.45

Price Target $6.25

Cash Flow

FCF Yield -12.0%

SBC Adj. FCF Yield -14.3%

SBC Impact -19.1%

Margins

Gross Margin -48306.4%

Operating Margin -323306.5%

FCF Margin -246974.2%

Growth (CAGR)

Revenue 3Y | 5Y -123.3% | -65.4%

Dil EPS 3Y | 5Y 35.2% | 22.4%

FCF 3Y | 5Y -3.3% | -3.1%

Returns

ROA -17.4%

ROE -31.4%

ROIC -19.5%

Financial Health

Net Cash

$291.58M

Current Ratio 26.78

Interest Coverage -28.34

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, prev...

Sector Healthcare

Industry Biotechnology

Employees 57

IPO Date May 25, 2017

Website altimmune.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$6.25

Upside

+91.13%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞